← Theranostic Atlas Therapy radar Imaging radar All targets Molecules Français Molecules
PSMA-1007 Target PSMA Class Small molecule (urea, fluoronicotinamide)
8 ongoing trials
1 radiolabelled forms
1 approved products
500 publications (PubMed)
Structure 3D 2D
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.
Properties (PubChem) Molecular formula C54H64F3N9O18 Molar mass (g/mol) 1,184.1 Exact mass (Da) 1,183.4321 H-bond donors 12 H-bond acceptors 22 Rotatable bonds 31 Heavy atoms 84 InChIKey QQFSTGSNRLIZGD-ACXPFIKISA-N PubChem record CID 153327302 ↗ IUPAC name [5-[[(2S)-4-carboxy-1-[[(2S)-4-carboxy-1-[[4-[[(2S)-1-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]phenyl]methylamino]-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]carbamoyl]-2-pyridinyl]-trimethylazanium;2,2,2-trifluoroacetate SMILES C[N+](C)(C)C1=NC=C(C=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC2=CC=C(C=C2)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O.C(=O)(C(F)(F)F)[O-] Radiolabelled forms Form Use Molar mass (labelled form) Ongoing trials Most advanced phase Approval [¹⁸F]PSMA-1007 Syntheses and QC ↗ Imaging — 8 Phase 3 Radelumin EU FR
Atlas trials whose studied drug or title names this vector, with this radionuclide.
Trial Phase Status Sponsor Countries [18F]PSMA-1007 NCT06122584 · Prostate – localised / recurrence Phase 3 Recruiting ABX advanced biochemical compounds GmbH 6 [68Ga]Ga-PSMA-11 2023-504917-54-00 · Prostate – localised / recurrence Phase 3 Recruiting Karolinska University Hospital 1 [68Ga]Ga-PSMA-11 2024-518171-59-00 · Prostate – other Phase 3 Recruiting Canisius Wilhelmina Ziekenhuis 1 [18F]PSMA-1007 NCT05520255 · Prostate – other Phase 3 Recruiting University of Alberta 1 P-GAP · [18F]PSMA-1007 NCT06003556 · Prostate – other Phase 2 Recruiting University of Alberta 1 GUIDE PSMA PET · Other PSMA ligand NCT07258056 · Prostate – other No phase Recruiting Mads Ryo Jochumsen 1 PRIDE2-PC · [18F]PSMA-1007 NCT07568613 · Prostate – other No phase Recruiting German Oncology Center, Cyprus 1 [18F]PSMA-1007 NCT06723665 · Prostate – other No phase By invitation Affiliated Hospital of Jiangnan University 1
Published results · 1 2026-07 PRISMA-PET · negativeIn 385 patients randomized at diagnosis, staging with PSMA-1007 PET classifies fewer patients as non-metastatic than sodium fluoride PET (69% vs 77%), but progression-free survival does not differ significantly (HR 0.74, p = 0.19). A favourable trend in high-risk patients; longer follow-up needed. Eur Urol Open Sci ↗
500 publications in PubMed for the query below; the most recent:
"PSMA-1007"[tiab] OR "PSMA1007"[tiab]
Laying the groundwork for future health economic evaluation of [(18)F]PSMA PET/CT in guiding treatment decisions for metastatic castration-resistant prostate cancer patients Eur J Radiol, 2026 Diagnostic accuracy of (18)F-PSMA-1007 PET/CT and bone scintigraphy for detecting bone metastases in prostate cancer Jpn J Radiol, 2026 Prospective evaluation of the PRIMARY score using [(18)F]PSMA-1007 PET/MRI in second-line prostate biopsies after negative MRI Eur J Nucl Med Mol Imaging, 2026 Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study Eur J Nucl Med Mol Imaging, 2026 Development and validation of a preoperative (18)F-PSMA-1007 PET/MR prognostic model for predicting biochemical recurrence in prostate cancer: a multicentre study Eur J Nucl Med Mol Imaging, 2026 Acridine-Based [68Ga]Ga- and [18F]AlF-Labeled PSMA Radiotracers Enabling High-Contrast PET Imaging with Minimized Undesired Retention J Med Chem, 2026 Comparative analysis of PSMA-RADS Version 2.0 versus bone uptake metastatic probability (BUMP) score for characterising focal bone uptake on [18F]PSMA-1007 PET/CT in prostate cancer - a multicentre evaluation Eur J Nucl Med Mol Imaging, 2026 Benign Hyperplastic Nodule in the Peripheral Zone of the Prostate Mimicking Prostate Cancer on 18 F-PSMA-1007 PET/CT Clin Nucl Med, 2026 Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
Cite this page PSMA-1007. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/psma-1007/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.